Intensive Care Medicine

, Volume 29, Issue 10, pp 1840–1843

Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus

  • Véronique Boussaud
  • Antoine Parrot
  • Charles Mayaud
  • Marie Wislez
  • Martine Antoine
  • Clément Picard
  • Françoise Delisle
  • Jérome Etienne
  • Jacques Cadranel
Brief Report

Abstract

Three new consecutive cases of life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus are presented, focusing on the particular clinical presentation of this new entity. Between December 1999 and March 2001, three adults aged from 23 to 67 years were admitted to our respiratory intensive care unit for massive hemoptysis and septic shock associated with community-acquired Staphylococcus aureus pneumonia. Isolates were sent to the Centre National de Référence des Toxémies Staphylococciques in Lyon, France, where they were found to secrete Panton-Valentive leukocidin. The clinical course was similar in the three patients, with massive hemoptysis and septic shock necessitating mechanical ventilation. Two patients died rapidly; necropsy showed pulmonary vascular necrosis in one of them. The third patient recovered after appropriate antibiotic therapy. Leukocidin/neutrophil interactions in the pulmonary vasculature may cause severe hemoptysis in patients with community-acquired Staphylococcus aureus pneumonia secreting Panton-Valentine leukocidin. Adult patients with massive hemoptysis and suspected community-acquired pneumonia should receive antibiotic regimens covering Staphylococcus aureus.

Keywords

Staphylococcus aureus Pneumonia Hemoptysis Adult respiratory distress syndrome (ARDS) 

References

  1. 1.
    Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A (1999) Etiology of community acquired pneumonia: impact of age, morbidity and severity. Am J Respir Crit Care Med 160:397-405PubMedGoogle Scholar
  2. 2.
    Leroy O, Georges H, Beuscart C, Guery B, Coffinier C, Vandenbussche C, Thevenin D, Beaucaire G (1996) Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score. Intensive Care Med 22:1307-1314CrossRefPubMedGoogle Scholar
  3. 3.
    Woodhead MA, Radvan J, MacFarlane JT (1987) Adult community acquired staphylococcal pneumonia in the antibiotic era: a review of 61 cases. QJM 64:783-790PubMedGoogle Scholar
  4. 4.
    Watanakunakorn C (1987) BacteremicStaphylococcal aureus pneumonia. Scand J Infect Dis 19:623-627PubMedGoogle Scholar
  5. 5.
    Campion A, Cremer R, Leteurtre S, Fourier C, Leclerc F (2000) Pneumopathie communautaire fatale à Staphylocoque doré sécréteur de la leucocidine de Panton et Valentine. Reanim Urgences 9:301-304Google Scholar
  6. 6.
    Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piemont Y, Brousse N, Floret D, Etienne J (2002) Association betweenS. aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753-759CrossRefPubMedGoogle Scholar
  7. 7.
    Prevost G, Couppie P, Prevost P, Gayet S, Petiau P, Cribier B, Monteil H, Piemont Y (1995) Epidemiological data onStaphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 42:237-245PubMedGoogle Scholar
  8. 8.
    Dufour P, Gillet Y, Bes M, Lina G, Vandenesch F, Floret D, Etienne J, Richet H (2002) Community acquired methicillin-resistant Staphylococcus aureus infection in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 35:19-24CrossRefGoogle Scholar
  9. 9.
    Fine MJ, Orloff JJ, Arisumi D, Fang GD, Arena VC, Hanusa BH, Yu VL, Singer DE, Kapoor WN (1990) Prognosis of patients hospitalised with community-acquired pneumonia. Am J Med 88 (5):1N-8NGoogle Scholar
  10. 10.
    Lina G, Piemont Y, Godail-Gamot, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J (1999) Involvement of Panton-Valentine leukocidin-producingStaphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29:1128-1132CrossRefPubMedGoogle Scholar
  11. 11.
    Gladstone GP, Van Heyningen WE (1957) Staphylococcal leucocidins. Br Exp Pathol 38:123-137Google Scholar
  12. 12.
    Couppie P, Cribier B, Prevost G (1994) Leukocidin fromStaphylococcus aureus and cutaneous infections: an epidemiologic study. Arch Dermatol 130:1208-1209CrossRefPubMedGoogle Scholar
  13. 13.
    Hensler T, Koller M, Prevost G, Piemont Y, Konig W (1994) GTP-binding proteins are involved in the modulated activity of humans neutrophils treated with the Panton-Valentine leukocidin fromStaphylococcus aureus. Infect Immun 62:5281-5289PubMedGoogle Scholar
  14. 14.
    Ward PD, Turner WH (1980) Identification of Staphylococcal Panton-Valentine leukocidin as a potent dermonecrotic toxin. Infect Immun 28:393-397PubMedGoogle Scholar
  15. 15.
    Konig B, Prevost G, Piemont Y, Konig W (1995) Effects ofStaphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis 171:607-613PubMedGoogle Scholar
  16. 16.
    Finch RG, Woodhead MA (1998) Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 55:31-45PubMedGoogle Scholar
  17. 17.
    Pea L, Roda L, Boussaud V, Lonjon B (2003) Desmopressin therapy for massive hemoptysis associated with severe leptospirosis. Am J Respir Crit Care Med 167:726-728CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Véronique Boussaud
    • 1
  • Antoine Parrot
    • 1
  • Charles Mayaud
    • 1
  • Marie Wislez
    • 1
  • Martine Antoine
    • 2
  • Clément Picard
    • 1
  • Françoise Delisle
    • 3
  • Jérome Etienne
    • 4
  • Jacques Cadranel
    • 1
  1. 1.Service de Pneumologie et de Réanimation RespiratoireHôpital Tenon-Université Paris VIParisFrance
  2. 2.Service d'Anatomie-pathologiqueHôpital Tenon-Université Paris VIParisFrance
  3. 3.Service de BactériologieHôpital Tenon-Université Paris VIParisFrance
  4. 4.Centre National de Références des Toxémies Staphylococciques, INSERM E0230, IFR 62Faculté de Médecine, Université Claude Bernard Lyon ILyon cedex 08France

Personalised recommendations